Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Articles

The collaboration will use Andelyn’s viral vector process to produce clinical-grade material for an upcoming gene therapy trial.

Andelyn Biosciences Partners with Queen's University on GM2 Gangliosidosis Gene Therapy

Videos

This week’s content included Moderna's mRNA flu approval, CMO governance tips, OSTP’s deregulation push, a $2 billion oncology license, and July's regulatory wrap-up.

PharmTech Weekly Roundup—August 7, 2026

Dr. Hui-Yin (Harry) Li is president and CEO of Wilmington PharmaTech.

PharmTech spoke with Dr. Hui-Yin (Harry) Li, president and CEO of Wilmington PharmaTech, about steps that should be taken to build a productive relationship between sponsor and contract organizations.

How to Maintain a Productive Sponsor-CMO Relationship

Katy MacLellan is Technical Team Leader, Symbiosis.

Lauren Nolan is Senior Director, Operations, Sterile Injectables, Kindeva.

Yash Sabharwal is CEO and Co-Founder, QbDVision.

Judyta Suskiewicz is Director Business Development, Mabion.

In part 2 of this 2-part discussion, our panelists explain how to maintain technical oversight without micromanaging and how one can align tech transfer and regulatory strategies to avoid commercial supply gaps.

Technology Transfer Between Contractors, A Panel Discussion, Part 2

Campbell Bunce is Chief Scientific Officer at Abzena.

Vice President – Business Development
LGM Pharma

CEO & Managing Director
Neuland Laboratories

Associate Director, IT Applications
Hikma

Founder, Kolter AI | Managing Partner, Kamet Consulting Group | Pharma & medtech M&A integrations, divestitures, tech transfers & CMC changes | Ex-PwC

Henrik Johanning is CEO and specialist, Genau & Co, Denmark. He is also a member of Pharmaceutical Technology Europe’s Editorial Advisory Board.

Pharma manufacturing and development experts reassess their 2026 predictions for the industry and look ahead to the second half of the year.

Midyear 2026 Industry Report: Taking Stock of Pharma Manufacturing, AI, and Regulatory Trends

In part 1 of this 2-part discussion, our panelists explain how to structure a tech transfer package, handle gaps in process understanding, and qualify analytical methods.

Technology Transfer Between Contractors, A Panel Discussion, Part 1

Campbell Bunce, chief scientific officer at Abzena, provides an update on the momentum in antibody-oligonucleotide conjugates development and the operational pressures shaping CDMO/CRO strategy for the rest of 2026.

Midyear 2026 Check In: Campbell Bunce of Abzena Talks Antibody-Oligonucleotide Conjugates and Development Timelines

Campbell Bunce, chief scientific officer at Abzena, revisited his 2026 industry predictions on the direction of the biologics and bioconjugate market and gives an update on ADCs.

Midyear 2026 Check in: Abzena’s Campbell Bunce on Trends in Antibody Drug Conjugates

Neuland's Saharsh Davuluri checks in on Chinese out-licensing, peptide capacity, and CDMO agility six months after his December 2025 predictions.

Saharsh Davuluri's Midyear Take on the Shifting CDMO Landscape Covers Out-Licensing, Agility, and Investment Surprises

A proposed rule by the agency would create a streamlined registration pathway for advanced distributed manufacturing establishments. 